Insider Transactions in Q2 2022 at Deciphera Pharmaceuticals, Inc. (DCPH)
Insider Transaction List (Q2 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 16
2022
|
Daniel Lee Flynn Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,768
-3.69%
|
$17,680
$10.75 P/Share
|
|
Jun 16
2022
|
Thomas Patrick Kelly Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,768
-3.7%
|
$17,680
$10.75 P/Share
|
|
Jun 16
2022
|
Daniel C. Martin Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,311
-2.58%
|
$13,110
$10.75 P/Share
|
|
Jun 16
2022
|
Jama Pitman SVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,298
-3.42%
|
$12,980
$10.75 P/Share
|
|
Jun 16
2022
|
Matthew L Sherman EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,768
-2.25%
|
$17,680
$10.75 P/Share
|
|
Apr 29
2022
|
Brightstar Associates LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,478,978
+7.57%
|
$14,789,780
$10.0 P/Share
|